



6336 17th Street Circle East
Sarasota, Florida 34243
Phone: (941) 727-4370
CPCMedDevices.com
Symbol: CPCF

Company Announcement

CPC Adds Key Bench Strengths to Medical and Technical Advisory Team

Sarasota, Fla., Tuesday, December 23, 2008 —CPC of America, Inc. (OTCBB: CPCF.OB), a company focused on the development of therapeutic devices that enhance the quality of patient care in endovascular procedures, announced the addition of three medical and technical advisors to its team. Dr. Olexander Hnojewyj, Dr. James L. Rogers and Richard E. Anderson will add strategically important bench strengths to the team's expertise as they work to develop MedClose™, an investigational*-stage vascular closure system (VCS) that is intended to seal the femoral arterial puncture site following diagnostic or interventional catheterization procedures. Information on CPC's advisory team can be found at CPC's enhanced corporate Web site, CPCMedDevices.com.

As a medical advisor, Olexander Hnojewyj, Ph.D. will add deep experience to the team, in the development of medical devices used in the treatment of vascular disease. Over the past seven years, he has conducted extensive research related to vascular closure sealants and has secured multiple patents and patent applications related to vascular closure.

As Bio-Statistician, James L. Rogers, Ph.D. will oversee clinical data management and statistical analysis for international clinical trials for the MedClose™ VCS. Dr. Rogers has handled numerous pre-clinical, clinical and post-approval trials for leading US and European pharmaceutical and medical device companies.

Richard E. Anderson will play a pivotal role as CPC looks to secure ISO and EN certification. He holds more than 30 years of experience in quality assurance and regulatory affairs. He has worked with numerous early-stage device companies to design systems that enhance the quality, productivity and efficiency of manufacturing and has also worked with a variety of regulatory bodies, including the FDA and European Notified Bodies and Competent Authorities.

"As we build our operational capabilities, the newest additions to our team of advisors are vital to our future success," said Rod Shipman, chairman and chief executive officer of CPC of America. "With the combined expertise and experience of our medical, technical and research advisors, we are in a strong position to pursue global commercialization of the MedClose™ VCS in an effort to provide a safe, reliable closure system that reduces time to hemostasis and allows for faster patient ambulation and, when necessary, wound re-access."

About CPC

CPC of America develops therapeutic devices for use in endovascular procedures. CPC's current focus is the completion of development and testing of the MedClose™ vascular closure system, an internal puncture-closing system for use in catheter laboratories.

Forward Looking Statements

The statements contained in this press release that are not historical are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements, without limitation, regarding the Company's expectations, beliefs, intentions or strategies regarding the future. Such forward-looking statements relate to, among other things: (1) the Company's continuing development of its MedClose™ vascular closure system, (2) the Company's expectations concerning regulatory approvals of the MedClose system and the commencement of revenue producing operations based on the sale or licensing of the MedClose, (3) the business relationship between the Company and new parties and the expected benefits to the Company from such relationship, and (4) the commencement of manufacturing of the MedClose system. These statements are qualified by important factors that could cause the Company's actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to: (1) the Company's ability to finance the continued development and commencement of manufacturing of the MedClose system, (2) regulatory approvals of the MedClose system, (3) the general risks and uncertainties inherent in any new business relationship such as the one recently entered into between the Company and its new consultants, and (4) those other risks and factors described from time to time in the Company's reports filed with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and subsequently filed Forms 10-Q and Forms 8-K. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur

###

Contact: Lindsey Jurca, FD, at +1 (213) 452-6459